Skip to main content

Taro Pharmaceutical Industries Ltd. (TARO)

NYSE: TARO · IEX Real-Time Price · USD
62.58 -1.31 (-2.05%)
Oct 22, 2021 10:56 AM EDT - Market open
Market Cap2.42B
Revenue (ttm)578.45M
Net Income (ttm)29.50M
Shares Out37.93M
EPS (ttm)0.77
PE Ratio81.06
Forward PE15.70
Dividendn/a
Ex-Dividend Daten/a
Volume287
Open63.77
Previous Close63.89
Day's Range62.58 - 62.58
52-Week Range56.53 - 80.00
Beta1.02
AnalystsBuy
Price Target80.00 (+27.8%)
Est. Earnings DateOct 27, 2021

About TARO

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprises allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, ...

IndustryPharmaceuticals
Founded1959
CEOUday Baldota
Employees1,417
Stock ExchangeNYSE
Ticker SymbolTARO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for TARO stock is "Buy" and the 12-month stock price forecast is 80.00.

Price Target
$80.00
(27.84% upside)
Analyst Consensus: Buy

News

Taro to Announce Second Quarter Results on October 28, 2021

HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO TO ANNOUNCE SECOND QUARTER RESULTS ON OCTOBER 28, 2021

23 hours ago - Business Wire

Earnings Preview: Taro Pharmaceutical (TARO) Q2 Earnings Expected to Decline

Taro (TARO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 day ago - Zacks Investment Research

Taro Pharmaceutical (TARO) Q1 Earnings and Revenues Beat Estimates

Taro (TARO) delivered earnings and revenue surprises of 29.76% and 7.23%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Taro Provides Results for Quarter Ended June 30, 2021

HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO PROVIDES RESULTS FOR QUARTER ENDED JUNE 30, 2021

2 months ago - Business Wire

Taro to Announce First Quarter Results on July 27, 2021

HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO TO ANNOUNCE FIRST QUARTER RESULTS ON JULY 27, 2021

3 months ago - Business Wire

Taro Pharma (TARO) Sees Hammer Chart Pattern: Time to Buy?

Taro Pharmaceutical Industries (TARO) has been struggling lately, but the selling pressure may be coming to an end soon.

3 months ago - Zacks Investment Research

Taro Announces Resignation of Chief Financial Officer

HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO ANNOUNCES RESIGNATION OF CHIEF FINANCIAL OFFICER

3 months ago - Business Wire

Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2021

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Annual Report on Form 20-F Available for Fiscal Year Ended March 31, 2021

4 months ago - Business Wire

Taro Provides Results for the Year Ended March 31, 2021

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Provides Results for the Year Ended March 31, 2021

5 months ago - Business Wire

Earnings Preview for Taro Pharmaceutical Indus

Taro Pharmaceutical Indus (NYSE:TARO) unveils its next round of earnings this Wednesday, May 19. Here is Benzinga's everything-that-matters guide for the earnings announcement.

5 months ago - Benzinga

Taro to Announce Full Year Results on May 19, 2021

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro to Announce Full Year Results on May 19, 2021

5 months ago - Business Wire

Taro Pharmaceutical Industries Ltd. (TARO) CEO Uday Baldota on Q2 2021 Results - Earnings Call Transcript

Taro Pharmaceutical Industries Ltd. (TARO) CEO Uday Baldota on Q2 2021 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Taro Pharmaceutical (TARO) Q2 Earnings and Revenues Top Estimates

Taro (TARO) delivered earnings and revenue surprises of 53.25% and 14.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Taro Pharmaceutical (TARO) Misses Q1 Earnings and Revenue Estimates

Taro (TARO) delivered earnings and revenue surprises of -34.48% and -25.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Why the FDA's Drug Competition Action Plan Is Bad News for Generic Pharmaceutical Stocks

Here's why a new initiative by the FDA to reduce drug prices is great for patients but should raise the alarm among pharmaceutical investors.

Other symbols:ANIPLCIPFETEVA
1 year ago - The Motley Fool

Taro Pharmaceuticals: Strong Balance Sheet and Strong Competition

Value investors like companies with strong balance sheets and no debt; it means there are no worries about the company going broke or getting into serious financial trouble.

1 year ago - GuruFocus

Taro Pharmaceutical Industries Ltd.'s (TARO) CEO Uday Baldota on Q4 2020 Results - Earnings Call Transcript

Taro Pharmaceutical Industries Ltd.'s (TARO) CEO Uday Baldota on Q4 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Taro Pharmaceutical (TARO) Misses Q4 Earnings Estimates

Taro (TARO) delivered earnings and revenue surprises of -7.19% and 3.98%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Former Taro Pharmaceutical VP Of Sales And Marketing Indicted for Price Fixing

Taro Pharmaceutical Industries Ltd (NYSE: TARO) former Vice President of Sales and Marketing Ara Aprahamian has been indicted by the Justice Department for price-fixing and bid-rigging on Tuesday, Reute...

1 year ago - Benzinga

Taro Pharmaceutical (TARO) Surpasses Q3 Earnings Estimates

Taro (TARO) delivered earnings and revenue surprises of 14.29% and -14.14%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Taro Pharmaceutical Industries Ltd. (TARO) CEO Uday Baldota on Q2 2020 Results - Earnings Call Transcript

Taro Pharmaceutical Industries Ltd. (TARO) CEO Uday Baldota on Q2 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Taro Pharmaceutical (TARO) Q2 Earnings and Revenues Lag Estimates

Taro (TARO) delivered earnings and revenue surprises of -15.12% and -4.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Taro Pharmaceutical (TARO) Earnings Expected to Grow: Should You Buy?

Taro (TARO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Taro Pharmaceutical (TARO) to Report Q1 Results: Wall Street Expects Earnings Growth

Taro (TARO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 years ago - Zacks Investment Research

Why Taro Pharmaceutical (TARO) Could Be Positioned for a Slump

Taro Pharmaceutical (TARO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

2 years ago - Zacks Investment Research